Scarica l'app Stockscreener
38.60
1.71%
0.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$38.05
Aprire:
$38.11
Volume 24 ore:
294.32K
Relative Volume:
0.20
Capitalizzazione di mercato:
$4.63B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-7.3384
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+0.08%
1M Prestazione:
+2.65%
6M Prestazione:
-23.00%
1 anno Prestazione:
-31.20%
Intervallo 1D:
$37.68
$39.14
Intervallo di 1 settimana:
$36.77
$39.45
Portata 52W:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
38.67 | 4.66B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.25 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.88 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.19 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.04 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.06 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics Names Jim Daly to Board of Directors - The Globe and Mail
Cytokinetics appoints James Daly to board of directors - Investing.com
Cytokinetics Appoints James M. Daly to Board of Directors - Quiver Quantitative
Cytokinetics Appoints James Daly to Board with Commercialization Expertise. - AInvest
Former Incyte & Amgen Commercial Leader Jim Daly Joins Cytokinetics Board as Company Preps Commercial Push - Stock Titan
Cytokinetics Inc Announces Stock Options and RSUs for New Employees Amid Ongoing Cardiovascular Advancements - AInvest
Cytokinetics EVP Malik sells $76k in shares - Investing.com
Cytokinetics EVP Malik sells $76k in shares By Investing.com - Investing.com UK
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants - Stock Titan
Cytokinetics Incorporated Inches Above Key Support — Safe to Hold2025 Volatility Report & High Return Trade Guides - 선데이타임즈
Will Cytokinetics Incorporated Recover After Recent DeclineJuly 2025 Analyst Calls & AI Driven Stock Movement Reports - newsimpact.co.kr
Is Cytokinetics Incorporated’s ROE strong enoughJuly 2025 Pullbacks & Free High Return Stock Watch Alerts - thegnnews.com
Cytokinetics (CYTK) Receives Buy Rating from Mizuho Securities with $84 Price Target - AInvest
Cytokinetics CEO Cashes In on Stock Sale - TipRanks
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings - MSN
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape By Investing.com - Investing.com Canada
Cytokinetics, Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCYTK - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Traders Expect Breakout From Cytokinetics Incorporated This WeekReal Trader Watchlist of Hot Stocks Released - beatles.ru
Cytokinetics: Promising Outlook with Aficamten’s Regulatory Progress and Strong Financial Health - TipRanks
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Gilead Sciences (GILD) and Cytokinetics (CYTK) - The Globe and Mail
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $53 to $120 - 富途牛牛
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com South Africa
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Aug 19 '25 |
Sale |
38.31 |
2,000 |
76,620 |
140,610 |
| Blum Robert I | President & CEO |
Aug 15 '25 |
Sale |
38.42 |
5,000 |
192,100 |
383,108 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Sale |
36.34 |
2,000 |
72,680 |
140,610 |
| Blum Robert I | President & CEO |
Jul 29 '25 |
Sale |
36.45 |
5,000 |
182,250 |
388,108 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Sale |
37.47 |
2,000 |
74,940 |
140,610 |
| Blum Robert I | President & CEO |
Jul 14 '25 |
Sale |
38.15 |
5,000 |
190,750 |
393,108 |
0.72%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):